Skip to main content

ORIGINAL RESEARCH article

Front. Pediatr.

Sec. Pediatric Rheumatology

Volume 13 - 2025 | doi: 10.3389/fped.2025.1535223

This article is part of the Research Topic Pediatric Rheumatology Care: Transitions from Child to Adult View all articles

Disease activity and treatment in patients with juvenile idiopathic arthritis before transfer to adult care: the first survey in China

Provisionally accepted
  • 1 Department of Rheumatology & Immunology, Children's Hospital of Chongqing Medical University, Chongqing, China
  • 2 National Clinical Research Center for Child Health and Disorders, Children's Hospital of Chongqing Medical University, Chongqing, China
  • 3 Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical University, Chongqing, China
  • 4 Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Children's Hospital of Chongqing Medical University, Chongqing, China

The final, formatted version of the article will be published soon.

    To analyze disease activity and treatment in patients with juvenile idiopathic arthritis (JIA) before transfer to adult care. Method. We retrospectively collected the clinical data of 230 JIA patients (range 14-18 years) in our center from January 2013 to December 2022. We evaluated the clinical features, disease activity, and medication use across various JIA subtypes. Results. 230 patients with JIA were included, and 144 (63%) were male. The distribution of JIA subtypes was dominated by enthesitis-related arthritis (32%), polyarthritis (31%), systemic JIA (27%), and oligoarthritis (10%). Disease activity assessment showed that 87 JIA (38%) were in active disease; while 143 JIA (62%) were in inactive disease, of which 59 patients achieved clinical remission on medicine and 13 patients achieved clinical remission off medicine. Conventional synthetic disease-modifying anti-rheumatic drugs were used in 83% of JIA patients, and biologics in 56%. Clinical characteristics and medication use differed between different subtypes of JIA. The oligoarthritis group had earlier disease onset (P=0.020) and longer disease duration (P=0.009) compared to other subtypes. Patients in the RF-positive polyarthritis group had a significantly lower rate of disease inactivity(39%, P=0.004) than the other subtypes, and a relatively lower proportion of patients achieved clinical remission on medication or discontinuation of medication(18%, P=0.024). Conclusions. Some JIA patients were still in active disease before transfer to adult clinics, failing to achieve clinical remission and discontinuation of medication, and required continued treatment.

    Keywords: juvenile idiopathic arthritis, pre-transfer, disease activity, Treatment, biologics

    Received: 27 Nov 2024; Accepted: 19 Mar 2025.

    Copyright: © 2025 Luo, Luo, Luo and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Xuemei Tang, Department of Rheumatology & Immunology, Children's Hospital of Chongqing Medical University, Chongqing, 400065, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more